Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2018-06-11 16:06:13
Reporting Period:
Accepted Time:
2018-06-11 16:06:13
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
816284 Celgene Corp CELG Pharmaceutical Preparations (2834) 222711928
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1190435 D Michael Casey C/o Celgene Corporation
86 Morris Avenue
Summit NJ 07901
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-06-07 27,750 $30.01 27,750 No 4 M Direct
Common Stock Disposition 2018-06-07 13,000 $78.77 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2018-06-07 27,750 $0.00 27,750 $30.01
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2018-06-18 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 116,804 Indirect Family Trust
  1. The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $78.77 to $78.81, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
  2. 14,750 shares were transferred to the Casey Family Trust U/A Dated 12/28/2004.
  3. The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
  4. The option was fully exercisable.
  5. The option was issued pursuant to the Company's 1995 Non-Employee Director's Incentive Plan.